Dupilumab (Sanofi) cemented its position as the top-selling inflammatory illness medication with its first-in-class IL-4Rα antagonist. In 2024, it generated $14.179 billion in sales (23% YoY growth).

Glycosylation produces a diverse and abundant repertoire of glycans, which are collectively known as the glycome. Glycans are one of the four fundamental macromolecular components of all cells ...

18 months after saying "no" to regular NHS funding for Sanofi and Regeneron's Dupixent (dupilumab) for severe asthma in initial guidance, NICE has now backed the drug. The final appraisal document ...

See the latest Regeneron Pharmaceuticals Inc stock price (REGN:XNAS), related news, valuation, dividends and more to help you make your investing decisions.

The aim is to prepare for the onset of biosimilar competition in the 2030s to Sanofi’s current immunology blockbuster Dupixent (dupilumab), which is predicted to top $14 billion in sales this ...

Alert FDA Approves Dupilumab for Bullous Pemphigoid Treatment with dupilumab improved disease remission and significantly reduced itching compared with placebo. Medscape Medical News, June 20, 2025 .

While no differences in assembly, antigen binding, and glycosylation occupancy were observed, both systems vary tremendously in terms of glycan structures and heterogeneity of glycosylation.